MPP re­cruits three gener­ic man­u­fac­tur­ers to ex­pand use of Vi­iV's in­jectable PrEP drug

Vi­iV Health­care has teamed up with the UN-backed Med­i­cines Patent Pool and three gener­ic man­u­fac­tur­ers to ex­pand ac­cess to med­i­cine that can pre­vent HIV.

Vi­iV and the Med­i­cines Patent Pool joint­ly an­nounced Thurs­day that the MPP signed sub-li­cens­ing agree­ments with Au­robindo, Cipla and Vi­a­tris to man­u­fac­ture gener­ics of a long-act­ing form of cabote­gravir for HIV pre-ex­po­sure pro­phy­lax­is (PrEP). As a re­sult of the agree­ment, the man­u­fac­tur­ers will be able to de­vel­op, man­u­fac­ture and sup­ply gener­ic ver­sions of cabote­gravir LA in 90 coun­tries — sub­ject to reg­u­la­to­ry ap­provals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER